Investigational drug · Phase 2
MDSY-1240
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MDSY-1240"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MDSY-1240", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple-Negative Breast Cancer (TNBC)
- Gastric Cancer (GC)
- Gastric Cancer Adenocarcinoma Metastatic
- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Hepatocellular Carcinoma Metastatic
- Classical Hodgkin Lymphoma Relapsed
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Head and neck cancer · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "MDSY-1240" as an intervention, largest first.
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruiting
Medsyn Biopharma, LLCIndustry
NCT07899632 · 75 participants (planned) · Start Nov 2026 · Primary completion Aug 2029
Drug: MDSY-1240 · For: Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic and 11 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Triple-Negative Breast Cancer (TNBC)
- ESG401Phase 33 trials
Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast
- Dual-target CAR-NK cellsEB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NKPhase 25 trials
Beijing Biotech · HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic)
- BreakVaxPhase 22 trials
BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.